New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
05:55 EDTDVA, DVA, WLP, WLP, MCK, MCK, CI, CI, BMY, BMY, MDT, MDT, COV, COV, BAYRY, BAYRY, EPOC, EPOC, AET, AET, AGN, AGN, HUM, HUM, BDX, BDXWharton School of Business to host a conference
19th Annual Wharton Healthcare Business Conference is being held in Philadelphia on February 14-15.
News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 22, 2015
10:15 EDTCIAnthem repeats FY15 revenue view of about $78.5B, consensus $78.16B
Repeats FY15 revenue view $78.5B, sees revenue for a combined Anthem (ANTM)-Cigna (CI) at >$115B. Anthem sees greater than 10% accretive to adjusted EPS in first year post-close, with accretion more than doubling in year two. Assuming the transaction closes on December 31, 2016, sees $17.00+ adjusted EPS in 2018. Anthem says expects to maintain dividend payout ratio policy, committed to retaining investment grade debt ratings. Says committed to de-levering over 2-year period post-close. Says deal is "compelling" for Cigna shareholders. Says Anthem has made "good faith efforts" to engage in valuation and governance discussions with Cigna, says fully prepared to proceed immediately to finalize due diligence and merger agreement negotiations. Comments from slides that will be presented on Anthem's update reaffirming its commitment to its $184 per share proposal for Cigna.
09:14 EDTCIOn The Fly: Pre-market Movers
Subscribe for More Information
09:02 EDTCICigna hits fresh highs after rejecting Anthem bid
Subscribe for More Information
09:02 EDTCIAnthem reiterates commitment to $184 per share proposal for Cigna
Subscribe for More Information
09:01 EDTCIAnthem reiterates commitment to $184 per share proposal for Cigna
Subscribe for More Information
08:52 EDTBMYPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
08:17 EDTMCKMcKesson appoints Kathy McElliogott as EVP, CIO, CTO
Subscribe for More Information
08:16 EDTHUM, CI, AETAnthem, Cigna deal would be negative for Catamaran, says Leerink
Subscribe for More Information
07:54 EDTAET, HUM, CIAnthem, Cigna deal likely to be consummated, says Leerink
Subscribe for More Information
07:16 EDTHUM, CI, AETAnthem should be bought after Cigna offer, says Stifel
After Anthem, (ANTM) offered to buy Cigna (CI) and the latter company rejected the bid, Stifel estimates that the deal would have been 10% accretive for Anthem in the first year and 20% accretive in the second year. The firm thinks that accretion from the deal will probably be higher than expected. It also recommends buying Aetna (AET) as it believes that the Anthem offer suggests that Aetna will benefit more than expected from its own deal. The firm is cautious on Humana (HUM), saying that it may lose two potential buyers in Anthem and Cigna, while Humana may retreat if Aetna does not acquire the company quickly.
06:51 EDTAET, HUM, CIHealth insurer tie-ups could cut competition, WSJ reports
Subscribe for More Information
06:37 EDTCI, AET, HUMHealth insurers may change policies based on King v. Burwell ruling, NYT says
Subscribe for More Information
06:03 EDTCICigna implied volatility of 37 at upper end of index
Subscribe for More Information
05:35 EDTBMYAllied-Bristol Life Sciences licenses IP from Harvard University
Allied-Bristol Life Sciences, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitmanís lab at the Harvard School of Dental Medicine. Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Childrenís Hospital, Professor Whitmanís lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction response pathway. Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases. The licensing agreement with Harvardís Office of Technology Development is among the first in a series of discovery and development projects that Allied-Bristol Life Sciences intends to pursue. The license to the technology from Professor Whitmanís lab will be held by a new ABLS subsidiary specifically formed to pursue further research and pre-clinical development of the technology and associated molecules.
June 21, 2015
18:17 EDTCICigna calls Anthem offer 'inadequate,' 'woefully skewed'
Subscribe for More Information
16:57 EDTCICigna says Anthem proposal not in interest of shareholders, Bloomberg reports
Cigna (CI) has sent a letter of rejection to the Anthem (ANTM) board of directors, reports Bloomberg. Notably, Cigna acknowledged that the combination of the two companies has some potential benefits under the right circumstances. However, the company also remarked that Anthem has "complications" related to its Blue Cross and Blue Shield membership, and also cited antitrust actions as well as Anthem's "lagging" shares.
16:50 EDTCICigna board unanimously rejects Anthem proposal, DJ says
Subscribe for More Information
16:03 EDTHUM, AET, CIAetna makes offer to acquire Humana, WSJ says
Subscribe for More Information
15:26 EDTCIAnthem publicized offer for Cigna in order to pressure company, WSJ says
Subscribe for More Information
12:42 EDTMDTMedtronic reports five-year follow-up results for Endurant AAA stent graft
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use